Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Human Factors
|
April 1, 1970
Computer-generated speech and man-computer interaction
S L Smith, N C Goodwin
Human Factors
|
June 1, 1971
Blink coding for information display
S L Smith, N C Goodwin
Immunogenetics
|
January 1, 1992
The B6.CE-Lyb-2c:Mup-1a mouse strain contains the interferon-alpha genes from C57BL/6
K A Gollahon, E A Boyse, N C Goodwin, et al.
The Pharmacogenomics Journal
|
June 14, 2017
Genetic background influences susceptibility to chemotherapy-induced hematotoxicity
D M Gatti, S N Weber, N C Goodwin, et al.
Nature Genetics
|
August 2, 2001
DelBank: a mouse ES-cell resource for generating deletions
N C Goodwin, Y Ishida, S Hartford, et al.
Human Molecular Genetics
|
January 12, 2001
Mouse models for the Wolf-Hirschhorn deletion syndrome
D Näf, L A Wilson, R A Bergstrom, et al.
Clinical Pharmacology and Therapeutics
|
June 29, 2012
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial
B Zambrowicz, J Freiman, P M Brown, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Human Factors
|
April 1, 1970
Computer-generated speech and man-computer interaction
S L Smith, N C Goodwin
Human Factors
|
June 1, 1971
Blink coding for information display
S L Smith, N C Goodwin
Immunogenetics
|
January 1, 1992
The B6.CE-Lyb-2c:Mup-1a mouse strain contains the interferon-alpha genes from C57BL/6
K A Gollahon, E A Boyse, N C Goodwin, et al.
The Pharmacogenomics Journal
|
June 14, 2017
Genetic background influences susceptibility to chemotherapy-induced hematotoxicity
D M Gatti, S N Weber, N C Goodwin, et al.
Nature Genetics
|
August 2, 2001
DelBank: a mouse ES-cell resource for generating deletions
N C Goodwin, Y Ishida, S Hartford, et al.
Human Molecular Genetics
|
January 12, 2001
Mouse models for the Wolf-Hirschhorn deletion syndrome
D Näf, L A Wilson, R A Bergstrom, et al.
Clinical Pharmacology and Therapeutics
|
June 29, 2012
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial
B Zambrowicz, J Freiman, P M Brown, et al.
Page
of 1